Drakes, George
Drakes, George was paid $25K by Medicaid between Feb 2021 and May 2021, across 8 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 40% of everything it billed.
33Billing provider infoDRAKES, GEORGE
OXON HILL, MD 20745
OXON HILL, MD 20745
33aNPI1174613327assigned 10/16/2006
33bProvider typeSpecialist
28Total paid$25K
24GClaims711
24DCodes billed8
24AFirst – last monthFeb 2021 – May 2021
Compared with peers
Next to other Specialist providers in Maryland
Rank by total paid#142 of 218
Median peer was paid$88K
This provider vs. median0.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 711 | $25K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 40% | 274 | 263 | $10K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 33% | 63 | 61 | $8K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 24% | 139 | 134 | $6K |
| 80305 | 2.5% | 77 | 74 | $620.62 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 34 | 31 | $164.27 |
| A6220 | Gauze, non-impregnated, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., with any size adhesive border, each dressing | <1% | 39 | 36 | $46.09 |
| A4215 | Needle, sterile, any size, each | <1% | 43 | 40 | $16.89 |
| A4657 | Syringe, with or without needle, each | <1% | 42 | 39 | $4.55 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.